AT-Patch (ATP-C130/ATP-C70)

by ATsens Co.  · Based in South Korea → — Ambulatory ECG Monitor for Continuous Cardiac Monitoring
Cardiology Family Medicine Internal Medicine

N/a
Regulatory Status Disclosed

Overview

The AT-Patch (ATP-C130/ATP-C70) is a revolutionary wearable electrocardiogram (ECG) monitor designed by ATsens Co., Ltd. for long-term continuous cardiac monitoring. It provides up to 14 days (ATP-C130) or 7 days (ATP-C70) of uninterrupted ECG recording, aiming to detect arrhythmias and other cardiac events that might be missed by shorter monitoring periods. The device is compact, lightweight (13g), and shower-proof (IP57 for ATP-C130, IP44 for ATP-C70), offering maximum patient comfort without the need for charging or electrode replacement during the monitoring period. It utilizes a high-performance sensor chip and short-length electrodes to ensure accurate and reliable ECG readings by reducing noise from body movement. The AT-Patch solution integrates with the AT-Note smartphone app (ATN-C130) for live ECG viewing and symptom recording, and the AT-Report software (ATR-C130/ATR-C70) for sophisticated and accurate ECG analysis, which employs machine learning algorithms for arrhythmia detection and provides detailed diagnostic reports for medical professionals.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist

Key Features

  • Up to 14 days of continuous ECG monitoring (ATP-C130)
  • High-performance sensor chip for accurate ECG signal acquisition
  • Short-length electrode to minimize motion artifact noise
  • Shower-proof design (IP57 for ATP-C130, IP44 for ATP-C70)
  • No charging or electrode replacement required during monitoring
  • Compact and lightweight (13g) for patient comfort
  • AT-Note smartphone app for live ECG viewing and symptom recording
  • AT-Report software with AI/machine learning algorithms for ECG analysis
  • Detection and classification of 17 types of arrhythmia
  • Doctor-centric 'Final Report' design with PDF export capability

Use Cases

  • Long-term continuous ECG monitoring for arrhythmia detection
  • Diagnosis of heart conditions for patients with transient symptoms (e.g., palpitations, dizziness, fatigue)
  • Early diagnosis and preventive treatment of heart disease
  • Real-time ECG monitoring of hospitalized patients (with ATP-T70 model)
  • Clinical trials and academic research in cardiology

What Physicians Need to Know

ECG/EKG Analysis Capability
The AT-Patch (ATP-C130/ATP-C70) is a wearable ECG monitoring device that records cardiac electrical activity for up to 14 or 7 days, respectively, using a single-lead patch. Its analysis software, AT-Report, utilizes machine learning algorithms to classify ECG patterns and analyze data for 17 types of arrhythmia. The device records ECG signals at 250 samples/sec, and its high-performance sensor chip and short-length electrode are designed to reduce noise and enhance ECG detection, including clear P-Waves for atrial fibrillation diagnosis. Comprehensive reports combine automated ECG analysis with physician over-read.
Arrhythmia Detection Accuracy
The AT-Patch's software algorithms are designed for accurate detection of arrhythmias and other cardiac events. Performance testing included metrics like sensitivity, positive predictive value, and false positive rate, supporting its effectiveness. The AT-Report software can analyze 17 types of arrhythmia. Studies have demonstrated its capability in detecting new-onset atrial fibrillation in high-risk patients. A study on Everest climbers showed the device detected 45 arrhythmias, including bradyarrhythmia and ventricular tachycardia, even in extreme environments. It has shown comparable diagnostic capability for early atrial fibrillation detection and in one study, found 47% additional diagnoses compared to Holter monitoring. Physician agreement with end-of-wear reports has been reported at 99%.
Heart Failure Risk Prediction
While the AT-Patch primarily focuses on ECG monitoring and arrhythmia detection, a study on new-onset atrial fibrillation in high-risk patients using the device noted a significant association between a previous history of heart failure and the detection of atrial fibrillation. The study also found that combining a CHA2DS2-VASc score u22654 with a history of heart failure significantly increased the atrial fibrillation detection rate to 24.4%. This suggests its utility in identifying arrhythmias that are relevant to heart failure management and risk stratification.
Cardiac Monitoring Integration
The AT-Patch system integrates an ECG recorder patch with the AT-Report analysis software and the AT-Note smartphone app. The AT-Note app allows for live ECG viewing and symptom recording via Bluetooth Low Energy (BLE) connectivity. ECG data is stored internally on the patch and transmitted to the analysis software after the monitoring period. For inpatient settings, the AT-Monitoring solution supports real-time ECG monitoring at a Nurses' Station, where the AT-Patch transmits signals via Bluetooth to a Gateway, which then sends data to the Cloud via Wi-Fi.
AHA/ACC Guideline Alignment
The AT-Patch has received multiple international certifications, including FDA, CE MDD, PMDA, and MFDS, indicating compliance with stringent medical device standards. The device's performance testing included compliance with IEC and ANSI/AAMI standards for ECG and medical electrical equipment. A study utilizing the AT-Patch for atrial fibrillation detection in high-risk patients employed the CHA2DS2-VASc score for risk stratification, a tool supported by AHA/ACC guidelines. ATsens is also an exhibitor at the AHA Scientific Sessions 2025, demonstrating engagement with the American Heart Association.
Real-Time Alert Capability
The AT-Note smartphone app provides a real-time ECG viewer, allowing patients and clinicians to observe ECG data as it's being recorded. Patients can press a power button on the AT-Patch to mark and record events when they experience symptoms, which are then documented in the AT-Note app. For hospital settings, ATsens' Smart ECG monitoring software (ATP-T70) is designed to provide real-time arrhythmia alarming for patients, enabling continuous monitoring at the Nurses' Station.
Physician Tip

The AT-Patch offers a convenient and reliable solution for long-term continuous ECG monitoring, crucial for detecting intermittent arrhythmias often missed by shorter-duration tests. Leverage the AT-Note app for patient symptom correlation with real-time ECG, enhancing diagnostic accuracy. The comprehensive AT-Report, with its AI-driven analysis and physician over-read, streamlines review and supports confident clinical decision-making, particularly for atrial fibrillation and other cardiac events. Consider its use in high-risk patients, especially those with a history of heart failure, to aid in early arrhythmia detection and subsequent management.

The AT-Patch system is designed with a core integration of the wearable patch, the AT-Note smartphone application (Android/iOS) for real-time viewing and symptom logging via Bluetooth, and the AT-Report PC software for in-depth ECG analysis. For hospital environments, the AT-Monitoring solution integrates the AT-Patch with a Gateway (Bluetooth to Wi-Fi) to transmit real-time ECG data to a central Nurses' Station for continuous patient monitoring and arrhythmia alarming. The system's use of Bluetooth Low Energy (BLE) facilitates seamless communication with compatible smart devices.

Details

Category Cardiology AI, Wearables & Remote Monitoring (RPM)
Pricing N/a — Not available publicly; typically involves direct sales to medical institutions or distributors.
DeploymentWearable device for patients; analysis software deployed on-premise at medical institutions.
Compliance
BAA AvailableUnknown AI-estimated
HIPAA CompliantUnknown AI-estimated
FDA Status 1 AI-estimated

The AT-Patch (ATP-C130) received U.S. FDA approval on October 10, 2022. The AT-Report ECG Analysis Software also secured U.S. FDA Clearance in May 2025.

Integrations
EHR Not specified
Specialties Cardiology, Family Medicine, Internal Medicine

What the Web Says

The AT-Patch (ATP-C130/ATP-C70) is a wearable, disposable ECG monitor designed for long-term continuous cardiac monitoring, offering up to 14 days of uninterrupted use. It is praised by medical professionals for its high accuracy in detecting arrhythmias, advanced technology, and patient-friendly features like being shower-proof and not requiring charging or electrode replacement during the monitoring period. The device is compatible with a smartphone app (AT-Note) for live ECG viewing and symptom recording, and an AI-based software (AT-Report) for sophisticated analysis by healthcare professionals. It has received certifications from major regulatory bodies including the FDA and CE MDD.

Overall: Positive

Strengths

  • High accuracy in ECG signal detection and arrhythmia identification, including P-waves for AF diagnosis.
  • Extended continuous monitoring for up to 14 days, increasing the chance of detecting intermittent arrhythmias.
  • Patient comfort and compliance due to its compact, lightweight, shower-proof design, and no need for charging or electrode replacement during wear.
  • Smartphone app (AT-Note) for real-time ECG viewing and easy symptom recording.
  • AI-powered analysis software (AT-Report) for efficient and accurate interpretation of ECG data by medical professionals.
  • Certifications from FDA, CE MDD, PMDA, and MFDS, ensuring safety and quality standards.

Limitations

  • Potential for skin adverse events, with some patients experiencing issues within the monitoring period.
  • Pricing information is not publicly available, making cost comparison difficult.
  • The AT-Note app's usage time may be affected by the individual communication environment.
  • AT-Report software is for medical institutions and not directly provided to patients.
  • Some general concerns about the accuracy of over-the-counter ECG devices compared to prescriptive ones, though AT-Patch is a medical device.

Based on reviews from: Medical Onex, Praxisdienst, ATsens, KBR, Medical AI Tools for Physicians, PubMed Central (PMC), Natural Heart Doctor

Last updated: 2026-07-18

Ratings & Reviews

No reviews yet. Be the first to review this tool!

Rate AT-Patch (ATP-C130/ATP-C70)

Clinical Value
Ease of Use
Integration
Support & Docs
Value for Money

Press & Coverage

Korea Biomedical Review
ATsens secures US supply deal for wearable ECG device AT-Patch
ATsens has signed a significant three-year supply agreement with a major U.S. distributor for its AT-Patch wearable ECG monitoring device and AT-Report analysis software, marking a full-scale entry into the U.S. market.
2025-07
Health Kyunghyang
AT-Report wins FDA clearance, boosting U.S. entry momentum
AT-Report, ATsens' ECG analysis software, received FDA clearance, complementing the earlier FDA clearance of the AT-Patch device and strengthening the company's position for U.S. market entry.
2025-10
FDA
AT-Patch (ATP-C130/ATP-C70) FDA 510(k) Premarket Notification
The FDA issued a 510(k) premarket notification for AT-Patch (ATP-C130/ATP-C70) on May 2, 2025, classifying it as a wearable ECG monitoring device for continuous cardiac electrical activity recording.
2025-05
Korea Biomedical Review
ATsens secures coverage for real-time monitoring system for hospitalized patients
ATsens announced that its AT-Monitoring system, which utilizes the AT-Patch for real-time inpatient ECG tracking, has qualified for insurance benefits under South Korea's Health Insurance Review and Assessment Service.
2025-11
PMC (Peer-Reviewed)
Artificial intelligence in modern clinical practice (Review)
This review article mentions AT-Patch (ATP-C130/ATP-C70) as one of the recent FDA-cleared cardiovascular AI tools, highlighting the rapid advancements in AI in cardiology for more accurate clinical judgments.
2026-01
Innolitics
2025 Year in Review: Cardiology AI/ML SaMD 510(k) Clearances
Innolitics' review of 2025 cardiology AI/ML FDA clearances includes AT-Patch (ATP-C130/ATP-C70) from ATsens Co.,Ltd., noting its clearance date and product codes.
2026-01
Physician Ai Tools
AT-Patch (ATP-C130/ATP-C70) vs Tempus ECG-Low EF
This comparison highlights AT-Patch as an integrated wearable device and AI software solution for continuous, long-term ambulatory ECG monitoring for arrhythmia detection, contrasting it with Tempus ECG-Low EF's focus on analyzing existing 12-lead ECG recordings for heart failure risk.
unknown
FDA
FDA 510(k) Applications Received During August, 2024
The FDA received the 510(k) application for AT-Patch (ATP-C130/ATP-C70) from ATsens Co.,Ltd. on August 30, 2024.
2024-08

Videos

Product demos, reviews, and walkthroughs for AT-Patch (ATP-C130/ATP-C70).

No videos found. Search YouTube directly

View all on YouTube

Frequently Asked Questions

The AT-Patch utilizes machine learning algorithms within its AT-Report analysis software to detect arrhythmias and other cardiac events from the recorded ECG data. This AI-powered analysis assists physicians by providing a sophisticated and accurate initial interpretation of long-term ECG recordings, streamlining the diagnostic process.
The AT-Patch (ATP-C130/ATP-C70) has received significant regulatory approvals, including FDA clearance in the U.S., CE MDD in Europe, PMDA in Japan, and MFDS in South Korea, classifying it as a Class IIa medical device. Its performance, including arrhythmia detection accuracy, has been tested for compliance with IEC and ANSI/AAMI standards for ECG and medical electrical equipment, and it has undergone software validation and cybersecurity testing.
A notable alternative to the AT-Patch for long-term continuous ECG monitoring is the Zio Patch (iRhythm Technologies), which is also a single-use patch-type ECG monitoring device. Both devices aim to provide extended cardiac monitoring to detect intermittent arrhythmias that might be missed by shorter-term tests.
Physicians should note that the AT-Patch is a single-lead device and is intended for patients 18 years or older. While it offers long-term monitoring, the AT-Report software provides analysis for review by the intended user and does not offer diagnostic interpretation or automated ECG analysis, requiring a physician's clinical judgment. Additionally, certain patient conditions like sensitive skin, wounds, or the presence of implantable electrical devices require consultation before use.
The AT-Patch records ECG data internally, which is then transferred to a PC for analysis using the AI-based AT-Report software after the monitoring period. This software generates detailed analysis reports that can be saved as PDFs, assisting medical professionals in reviewing results and making accurate diagnoses. Patients can also use the AT-Note smartphone app to view live ECG data and record symptoms, which provides valuable contextual information for the physician.
The AT-Patch system undergoes cybersecurity testing to ensure the protection of patient data. While specific details on encryption or data handling protocols were not extensively detailed, medical devices with FDA clearance are expected to adhere to stringent data security and privacy regulations, including those related to patient health information.
Specific pricing information for the AT-Patch (ATP-C130/ATP-C70) is not publicly available in the provided search results. For details on pricing, purchasing, and current reimbursement status, physicians should directly contact ATsens Co., Ltd. or their authorized distributors.

Related Tools

EchoMD AutoEF
Caption Health (formerly Bay Labs, now part of GE HealthCare)
Cardiology AI
EchoMD AutoEF is an FDA-cleared AI software that automates the selection of echocardiogram clips and calculates left ventricular ejection fraction (EF), enhancing efficiency and accuracy in cardiac assessments.
ECG-AI Cardiac Amyloidosis (CA) 12-Lead Algorithm
Anumana, Inc.
Cardiology AI
An AI algorithm for screening cardiac amyloidosis using standard 12-lead ECGs.
DEEPVESSEL Plaque
Keya Medical Technology Co., Ltd.
Cardiology AI
An AI software platform for coronary plaque analysis and quantification from CT angiography.
WatchMate Software
Anumana, Inc.
Cardiology AI
Anumana is an AI-driven health technology company from nference, developing and delivering ECG algorithms enabling early diagnosis and intervention.
syngo.CT Coronary Cockpit
Siemens Healthineers
Cardiology AI
syngo.CT Coronary Cockpit is an AI-powered software tool by Siemens Healthineers for efficient and accurate CT coronary angiography analysis.
HeartLung AI-CVD®
HeartLung Corporation
Cardiology AI
HeartLung AI-CVD® is an FDA-cleared AI-powered quantitative imaging tool that provides automated CT-derived measurements for assessing cardiovascular and multisystem risks opportunistically.

See all Cardiology AI tools →

Suggest an Edit → | Last Verified: 2026-04-17 | First Added: 2026-04-17
AI Tool Finder
AI-powered search. Results may not be comprehensive.